Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study

Mego, Michal; Chovanec, Jozef; Vochyanova-Andrezalova, Iveta; Konkolovsky, Peter; Mikulova, Milada; Rečková, Mária; Miškovská, Věra; Bystrický, Branislav; Beniak, Juraj; Medvecová, Lenka; Lagin, Adela; Světlovská, Daniela; Špánik, S.; Zajac, Vladimír; Mardiak, Jozef; Drgoňa, Ľuboš

doi:10.1016/j.ctim.2015.03.008

Cited by 175 publications

(160 citation statements)

References 32 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…However, these treatments generate diverse side effects which influence the quality of life of patients (1). Thus, different chemotherapeutic agents are being tested in combination with biologically active compounds to avoid these effects without comprising efficacy (12,13). …”

Section: Discussionmentioning

confidence: 99%

Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver

et al. 2017

View full text Add to dashboard Cite

Colorectal cancer (CRC) is an aggressive disease in which patients usually die due to its metastatic progression to the liver. Up to date, irinotecan is one of the most used chemotherapeutic agents to treat CRC metastasis with demonstrated efficacy. However, the severity of the side effects constitute the main limitation to its use in the treatment. Consequently, new complementary therapies are being developed to avoid these adverse effects while maintaining the efficacy of the antitumoral drugs. Ocoxin oral solution (OOS®) is a nutritional mixture containing biologically active compounds with demonstrated antitumoral and immunomodulatory effects. Thus, we aimed to analyze the effect of OOS® as a suitable complement to irinotecan therapy in the treatment of CRC metastasis to the liver. First, the effect of OOS®, irinotecan and the combination of both on the viability of C26 cells was tested in vitro and in vivo. Second, the expression of caspase-3, Ki67 and the macrophage infiltration by F4/80 marker was quantified in liver tissue sections by immunohistochemistry. Finally, mRNA microarray study was carried out on tumor cells isolated from tumor-bearing livers collected from mice subjected to the above treatments. Our results show that OOS® administered as a complementary therapy to irinotecan reduced tumor cell viability in vitro. Moreover, irinotecan administered either alone or in combination with 100 µl OOS® from the 7th day after tumor cell inoculation decreased the metastatic growth in the liver. Besides, several genes with binding and catalytic activities showed to be deregulated by RNA microarray analysis. In conclusion, OOS®, when administered as a complement to irinotecan, reduced the metastatic development of colorectal cancer to the liver. Additionally, the overall health state of the animals improved. These results point out OOS® as a potential supplement to the anti-tumoral treatments used in clinical settings in patients suffering from disseminated colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver

et al. 2017

View full text Add to dashboard Cite

show abstract

“…NCT01707641 (ClinicalTrials. gov, 2016c) is an ongoing trial evaluating the preventive effect of Lactobacillus on RT-CT-induced OM in HN cancer patients, while NCT02819960 trial is investigating the role of probiotics in preventing irinotecan-induced diarrhea (Mego et al, 2015). …”

Section: Management Of Gastrointestinal Mucositis: Current and Investmentioning

confidence: 99%

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

et al. 2017

View full text Add to dashboard Cite

Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have been recently reported. The ability to determine risk factors for mucositis, to early detect its onset, to assess correctly the degree of this toxicity and to plan its multidisciplinary management are all key elements to guarantee the quality of life of patients and to avoid useless dose reduction or interruption of treatment. The pathogenesis of mucositis is multifactorial and it is classily subdivided into oral and gastrointestinal mucositis according to its anatomic presentation. Treatment and patients’ related factors might help in predicting the frequency and the potential degree of symptoms onset. Here we discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments. Moreover, we focus on therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of mucositis in the next future.

show abstract

“…Para reduzir a severidade e incidência dessa complicação, observou-se que o uso dos probióticos é seguro 24,27 . A utilização de probióticos antes do início da radioterapia se mostrou benéfica, pois auxiliou na prevenção da diarreia, diminuindo sua incidência e severidade induzida por toxicidade gastrointestinal provocada pela quimioterapia 24,27 .…”

Section: Discussionunclassified

Uso De Pré, Pró E Simbióticos Como Coadjuvantes No Tratamento Do Câncer Colorretal

et al. 2017

View full text Add to dashboard Cite

Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study

Cited by 175 publications

References 32 publications

Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver

Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

Uso De Pré, Pró E Simbióticos Como Coadjuvantes No Tratamento Do Câncer Colorretal

Contact Info

Product

Resources

About